Consider the potential benefit of REVLIMID and risk of SPM.1
- Monitor patients for the development of SPM
- In clinical trials in patients with multiple myeloma receiving REVLIMID, an increase of hematologic plus solid-tumor SPM, notably AML and MDS, has been observed
Rd for NSCT NDMM.
- The frequency of AML and MDS cases in patients with NDMM treated with REVLIMID + low-dose dex without melphalan was 0.4%